1. Vigano D, Rubino T,
Parolaro D.
Molecular and cellular basis of cannabinoid and opioid interactions.
Pharmacol Biochem Behav. 2005, 81: 360-368
2. Rubino T, Forlani G, Vigano D, Zippel R, Parolaro D.
Ras/ERK signalling in cannabinoid tolerance: from behaviour to cellular
aspects. J Neurochem. 2005 May;93(4):984-91.
3. Vaccani A, Massi P, Colombo A, Rubino T, Parolaro D.
Cannabidiol inhibits human glioma cell migration through a cannabinoid
receptor-independent mechanism. Br J Pharmacol. 2005 Apr;144(8):1032-6.
4. Vigano D, Rubino T., Vaccani A, Bianchessi S, Marmorato P, Castiglioni
C, Parolaro D.
Molecular mechanisms involved in the asymmetric interaction between
cannabinoid and opioid systems. Neuropsychopharmacol. 2005 vol.
182:527-536
5. Vigano D, Valenti M, Cascio MG, Di Marzo V, Parolaro D, Rubino
T.
Changes in endocannabinoid levels in a rat model of behavioural
sensitization to morphine. Eur J Neurosci. 2004 Oct;20(7):1849-57.
6. Valenti M, Vigano D, Casico MG, Rubino T, Steardo L, Parolaro
D, Di Marzo V.
Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol
levels in rat brain. Cell Mol Life Sci. 2004 Apr;61(7-8):945-50
7. Rubino T, Forlani G, Vigano D, Zippel R, Parolaro D.
Modulation of extracellular signal-regulated kinases cascade by
chronic delta 9-tetrahydrocannabinol treatment. Mol Cell Neurosci.
2004 Mar;25(3):355-62.
8. Rubino T., Viganò D., Massi P. and Parolaro D.
Cellular mechanisms of Delta 9-tetrahydrocannabinol behavioural
sensatization”. Eur. J. Neurosci. 2003 17 (2), 325-330.
9. Viganò D., Cascio M., Rubino T., Fezza F., Vaccani A.,
Di Marzo V. and Parolaro D.
Chronic morphine modulates the contents of the cannabinoid, 2-arachidonoyl
glycerol, in rat brain. Neuropsycopharmacol. 2003, 28 (6), 1160-1167,.
10. Viganò D., Rubino T., Di Chiara G., Ascari I., Massi
P. and Parolaro D.
Mu opioid receptor signaling in morphine sensitisation. Neuroscience,
117 (4), 921-929, 2003.
11. Massi P, Vaccani A, Rubino T, Parolaro D.
Cannabinoids and opioids share cAMP pathway in rat splenocytes.
J Neuroimmunol. 2003 Dec;145(1-2):46-54,.
12. Parolaro D, Rubino T.
Is cannabinoid transmission involved in rewarding properties of
drugs of abuse? Br J Pharmacol. 2002, 136(8):1083-4.
13. Parolaro D, Massi P, Rubino T, Monti E.
Endocannabinoids in the immune system and cancer. Prostaglandins
Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):319-32.
14. Ponti W, Rubino T, Bardotti M, Poli G, Parolaro D.
Cannabinoids inhibit nitric oxide production in bone marrow derived
feline macrophages. Vet Immunol Immunopathol. 2001 Oct;82(3-4):203-14.
15. Rubino T, Vigano D, Massi P, Parolaro D.
The psychoactive ingredient of marijuana induces behavioural sensitization.
Eur J Neurosci. 2001 Sep;14(5):884-6
16. Rubino T, Vigano D, Costa B, Colleoni M, Parolaro D.
Loss of cannabinoid-stimulated guanosine 5'-O-(3-[(35)S]Thiotriphosphate)
binding without receptor down-regulation in brain regions of anandamide-tolerant
rats. J Neurochem. 2000 Dec;75(6):2478-84.
17. Rubino T, Vigano D, Massi P, Parolaro D.
Changes in the cannabinoid receptor binding, G protein coupling,
and cyclic AMP cascade in the CNS of rats tolerant to and dependent
on the synthetic cannabinoid compound CP55,940. J Neurochem. 2000
Nov;75(5):2080-6.
18. Rubino T, Massi P, Vigano D, Fuzio D, Parolaro D.
Long-term treatment with SR141716A, the CB1 receptor antagonist,
influences morphine withdrawal syndrome. Life Sci. 2000 Apr 21;66(22):2213-9.
19. Rubino T, Vigano' D, Massi P, Spinello M, Zagato E, Giagnoni
G, Parolaro D.
Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels
and cAMP-dependent protein kinase activity in some rat brain regions.
Neuropharmacology. 2000 Apr 27;39(7):1331-6.
20. Rubino T, Vigano D, Zagato E, Sala M, Parolaro D.
In vivo characterization of the specific cannabinoid receptor antagonist,
SR141716A: behavioral and cellular responses after acute and chronic
treatments. Synapse. 2000 Jan;35(1):8-14.
21. Bianchi M, Maggi R, Pimpinelli F, Rubino T, Parolaro D, Poli
V, Ciliberto G, Panerai AE, Sacerdote P.
Presence of a reduced opioid response in interleukin-6 knock out
mice. Eur J Neurosci. 1999 May;11(5):1501-7.
22. Massi P, Sacerdote P, Ponti W, Fuzio D, Manfredi B, Vigano
D, Rubino T, Bardotti M, Parolaro D.
Immune function alterations in mice tolerant to delta9-tetrahydrocannabinol:
functional and biochemical parameters. J Neuroimmunol. 1998 Dec
1;92(1-2):60-6.
23. Garcia-Gil L, Ramos JA, Rubino T, Parolaro D, Fernandez-Ruiz
JJ.
Perinatal delta9-tetrahydrocannabinol exposure did not alter dopamine
transporter and tyrosine hydroxylase mRNA levels in midbrain dopaminergic
neurons of adult male and female rats. Neurotoxicol Teratol. 1998
Sep-Oct;20(5):549-53.
24. Rubino T, Patrini G, Massi P, Fuzio D, Vigano D, Giagnoni G,
Parolaro D.
Cannabinoid-precipitated withdrawal: a time-course study of the
behavioral aspect and its correlation with cannabinoid receptors
and G protein expression. J Pharmacol Exp Ther. 1998 May;285(2):813-9.
25. Rubino T, Tizzoni L, Vigano D, Massi P, Parolaro D.
Modulation of rat brain cannabinoid receptors after chronic morphine
treatment. Neuroreport. 1997 Oct 20;8(15):3219-23.
26. Massi P, Patrini G, Rubino T, Fuzio D, Parolaro D.
Changes in rat spleen cannabinoid receptors after chronic CP-55,940:
an autoradiographic study. Pharmacol Biochem Behav. 1997 Sep;58(1):73-8.
27. Rubino T, Patrini G, Parenti M, Massi P, Parolaro D.
Chronic treatment with a synthetic cannabinoid CP-55,940 alters
G-protein expression in the rat central nervous system. Brain Res
Mol Brain Res. 1997 Mar;44(2):191-7.
28. Rubino T, Parenti M, Patrini G, Massi P, Parolaro D.
Morphine withdrawal syndrome and G protein expression: a study of
the time course in the rat central nervous system. Eur J Neurosci.
1995 Nov 1;7(11):2334-40.
29. Rubino T, Massi P, Patrini G, Venier I, Giagnoni G, Parolaro
D.
Chronic CP-55,940 alters cannabinoid receptor mRNA in the rat brain:
an in situ hybridization study. Neuroreport. 1994 Dec 20;5(18):2493-6.
30. Rubino T, Massi P, Patrini G, Venier I, Giagnoni G, Parolaro
D.
Effect of chronic exposure to naltrexone and opioid selective agonists
on G protein mRNA levels in the rat nervous system. Brain Res Mol
Brain Res. 1994 Jun;23(4):333-7. |